Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQJX34
|
|||
| Drug Name |
JS016
|
|||
| Synonyms |
LY-CoV016
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1/2 | [1] | |
| Company |
Lilly; Junshi Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 spike glycoprotein (S) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04780321) JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Lilly. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.